Sildenafil
Unchecked
PDE5 Inhibitor
Sildenafil
Viagra, Revatio
Sildenafil was the first PDE5 inhibitor (FDA-approved 1998) and remains the prototype. Originally developed for angina; repurposed after a famous trial-side-effect observation. Same molecule is marketed as Revatio for pulmonary arterial hypertension at lower individual doses but higher daily totals.
Blood pressure with concurrent antihypertensives or alpha-blockers.
Contraindicated with any nitrate, life-threatening hypotension. Caution with alpha-blockers, separate doses by ≥4 h. The "blue tint" visual side effect comes from PDE6 cross-reactivity in retinal cones.
Avanafil, Tadalafil, Vardenafil
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Pharmacokinetics
Absorption
~40%; reduced by high-fat meals.Distribution
Plasma protein binding ~96%.Metabolism
Hepatic via CYP3A4 (primary), CYP2C9.Elimination
Mainly fecal as metabolites.Interactions
No interactions reported yet.
Monitoring
Patient counseling
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
Summary
Classes
PDE5 Inhibitor
Pharmacy
Starting dose
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH)
Preparations
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio)
US FDA Max
100 mg/d (ED); 20 mg TID (PAH)
Pharmacology
Routes
Oral, IV (Revatio)
Onset
30–60 min
Duration
~4 h
Half-life
~4 h
Bioavailability
~40%
Pregnancy
Category B
Legal status
Rx-only in US
Purported mechanism
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation.